The federal judge overseeing hundreds of lawsuits involving Merck & Co.’s osteoporosis drug Fosamax wants to hear two additional “bellwether” cases beyond the two scheduled for later this year.

Merck is facing more than 900 cases in state and federal court generally alleging that the use of Fosamax can cause a jaw-destroying condition known as osteonecrosis and that Merck failed to properly warn of this risk. The cases are being heard individually.

Read the full Wall Street Journal story, “Judge Wants More ‘Bellwether’ Trials in Litigation Over Merck’s Fosamax